University closes PTSD studies after complaints from drug regulatorBMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i3891 (Published 12 July 2016) Cite this as: BMJ 2016;354:i3891
- Owen Dyer
Eight studies into an experimental drug to treat post traumatic stress disorder (PTSD) have been halted by New York University (NYU) and their principal investigator has resigned after a letter from the US Food and Drug Administration (FDA) warned that lapses in the conduct of the research jeopardized “subject safety and welfare, and raised concerns about the validity and integrity of the data collected at [the] site.”
The studies, sponsored by Pfizer, were trials of a fatty acid amide hydrolase (FAAH) inhibitor, a drug with effects on cannabinoid receptors, as a potential treatment for distress in patients with traumatic memories.
The FDA warning came in a …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial